✦ LIBER ✦

922Thalidomide / interleukin-2 in metastatic kidney cancer refractory to chemoimmunotherapy

✍ Scribed by A.J. Schrader; A. Heidenreich; A. Hegele; P. Olbert; Z. Varga; C.H. Ohlmann; Knobloch R. Von; R. Hoffmann

Book ID: 118647051
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 159 KB
Volume: 4
Category: Article
ISSN: 1569-9056
DOI: 10.1016/s1569-9056(05)80926-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Outpatient 5-fluorouracil +α-interferon

Outpatient 5-fluorouracil +α-interferon + interleukin-2 chemoimmunotherapy in metastatic renal cell cancer patients

✍ Ozlem ER; Metin OZKAN; Mustafa ALTINBAS; Hasan Senol COSKUN; Bulent ESER; Fevzi 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 96 KB

MP-16.20: Thalidomide in combination wit

MP-16.20: Thalidomide in combination with interleukin-2 for patients with metastatic renal cell carcinoma refractory to prior IL-2 and alpha-interferon treatment

✍ R. Shiroki; S. Mori; S. Miyakawa; M. Ichino; M. Hirano; M. Kusaka; K. Hayakawa; 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 63 KB

Activity of dose-dense outpatient intrav

Activity of dose-dense outpatient intravenous Interleukin-2 preceded by famotidine in metastatic clear cell cancer of the kidney

✍ Walter Quan Jr.,Francine M Quan 📂 Article 📅 2013 🏛 Springer (Biomed Central Ltd.) 🌐 English ⚖ 74 KB

Thalidomide reduces serum C-reactive pro

Thalidomide reduces serum C-reactive protein and interleukin-6 and induces response to IL-2 in a fraction of metastatic renal cell cancer patients who failed IL-2-based therapy

✍ Igal Kedar; Wilmosh Mermershtain; Hefziba Ivgi 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 341 KB

## Abstract Interleukin‐2 (IL‐2) has some antitumor activity in patients with renal cell carcinoma. It has been noted that response to IL‐2 and prognosis may be adversely affected by elevated serum levels of C‐reactive protein (CRP) or interleukin‐6 (IL‐6). We used thalidomide to treat patients wit

A phase 2 study of carboplatin plus doce

A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel

✍ Robert W. Ross; Tomasz M. Beer; Susanna Jacobus; Glenn J. Bubley; Mary-Ellen Tap 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB 👁 2 views

## Abstract ## BACKGROUND. Prostate cancer is the second leading cause of cancer mortality among men in the U.S. To the authors' knowledge, there is no proven, effective, second‐line therapy for docetaxel‐refractory disease. Recent data suggest that platinum salts may be effective when combined wi

Chemoimmunotherapy with dacarbazine, cis

Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: A randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group

✍ C.J.A. Punt; S. Suciu; M.A. Gore; J. Koller; W.H.J. Kruit; J. Thomas; P. Patel; 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 150 KB